达格列净在老年人群中的疗效与安全性:DECLARE-TIMI 58研究分析
DECLARE-TIMI 58研究评估达格列净对比安慰剂在2型糖尿病患者中的心肾结局,按年龄亚组分析显示,达格列净降低心血管死亡或心衰住院复合终点的疗效在各年龄组一致(交互P=0.5277),安全性与年龄无关。
要点
- 达格列净降低心血管死亡或心衰住院复合终点在各年龄组一致,交互P=0.5277。
- 达格列净未显著降低主要不良心血管事件发生率,交互P=0.7352。
- 严重生殖道感染和糖尿病酮症酸中毒不常见,但达格列净组更频繁,无年龄异质性。
核心结论
- 达格列净的总体疗效和安全性在各年龄组一致。
研究设计与样本
- DECLARE-TIMI 58研究为随机对照试验,评估达格列净对比安慰剂在2型糖尿病患者中的心脏和肾脏结局。
- 共纳入17,160例患者,其中<65岁9,253例,≥65至<75岁6,811例,≥75岁1,096例。
主要发现
- 达格列净降低心血管死亡或心衰住院复合终点:<65岁组HR 0.88(95%CI 0.72, 1.07),≥65至<75岁组HR 0.77(95%CI 0.63, 0.94),≥75岁组HR 0.94(95%CI 0.65, 1.36),交互P=0.5277。
- 达格列净未显著降低主要不良心血管事件:<65岁组HR 0.93(95%CI 0.81, 1.08),≥65至<75岁组HR 0.97(95%CI 0.83, 1.13),≥75岁组HR 0.84(95%CI 0.61, 1.15),交互P=0.7352。
- 次要预设心肾复合终点的相对风险降低在不同年龄组为18%至28%,无显著异质性。
- 严重低血糖达格列净对比安慰剂:<65岁组HR 0.97(95%CI 0.58, 1.64),≥65至<75岁组HR 0.50(95%CI 0.29, 0.84),≥75岁组HR 0.68(95%CI 0.29, 1.57),交互P=0.2107。
- 安全结局(骨折、容量不足、癌症、尿路感染、截肢)在达格列净与安慰剂间平衡,急性肾损伤减少,均与年龄无关;严重或导致停药的生殖道感染和糖尿病酮症酸中毒不常见,但达格列净组更频繁,无显著异质性(交互P值分别为0.1058和0.8433)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Data regarding the effects of sodium-glucose cotransporter 2 inhibitors in the elderly (age ≥65 years) and very elderly (age ≥75 years) are limited. RESEARCH DESIGN AND METHODS: The Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 assessed cardiac and renal outcomes of dapagliflozin versus placebo in patients with type 2 diabetes. Efficacy and safety outcomes were studied within age subgroups for treatment effect and age-based treatment interaction. RESULTS: Of the 17,160 patients, 9,253 were <65 years of age, 6,811 ≥65 to <75 years, and 1,096 ≥75 years. Dapagliflozin reduced the composite of cardiovascular death or hospitalization for heart failure consistently, with a hazard ratio (HR) of 0.88 (95% CI 0.72, 1.07), 0.77 (0.63, 0.94), and 0.94 (0.65, 1.36) in age-groups <65, ≥65 to <75, and ≥75 years, respectively (interaction P value 0.5277). Overall, dapagliflozin did not significantly decrease the rates of major adverse cardiovascular events, with HR 0.93 (95% CI 0.81, 1.08), 0.97 (0.83, 1.13), and 0.84 (0.61, 1.15) in age-groups <65, ≥65 to <75, and ≥75 years, respectively (interaction P value 0.7352). The relative risk reduction for the secondary prespecified cardiorenal composite outcome ranged from 18% to 28% in the different age-groups with no heterogeneity. Major hypoglycemia was less frequent with dapagliflozin versus placebo, with HR 0.97 (95% CI 0.58, 1.64), 0.50 (0.29, 0.84), and 0.68 (0.29, 1.57) in age-groups <65, ≥65 to <75, and ≥75 years, respectively (interaction P value 0.2107). Safety outcomes, including fractures, volume depletion, cancer, urinary tract infections, and amputations were balanced with dapagliflozin versus placebo, and acute kidney injury was reduced, all regardless of age. Genital infections that were serious or led to discontinuation of the study drug and diabetic ketoacidosis were uncommon, yet more frequent with dapagliflozin versus placebo, without heterogeneity (interaction P values 0.1058 and 0.8433, respectively). CONCLUSIONS: The overall efficacy and safety of dapagliflozin are consistent regardless of age.
引用
- Cahn A, Mosenzon O, Wiviott SD, et al. Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study. Diabetes Care. 2019. PMID: 31843945. doi:10.2337/dc19-1476
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。